Moss v. Wyeth, Inc.

872 F. Supp. 2d 154, 2012 U.S. Dist. LEXIS 69178, 2012 WL 1802445
CourtDistrict Court, D. Connecticut
DecidedMay 17, 2012
DocketNo. 3:04cv1511 (SRU)
StatusPublished
Cited by6 cases

This text of 872 F. Supp. 2d 154 (Moss v. Wyeth, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Connecticut primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Moss v. Wyeth, Inc., 872 F. Supp. 2d 154, 2012 U.S. Dist. LEXIS 69178, 2012 WL 1802445 (D. Conn. 2012).

Opinion

RULING ON SUPPLEMENTAL MOTION FOR SUMMARY JUDGMENT

STEFAN R. UNDERHILL, District Judge.

Before the court is Defendants’ Supplemental Motion for Summary Judgment Regarding Statute of Limitations And Commencement Date of Lawsuit (doc. # 326). Despite more than seven years of vigorous litigation, Defendants Wyeth, Inc. and Wyeth Pharmaceuticals, Inc. (collectively ‘Wyeth”) seek to end this case in the middle of trial by claiming that the case never formally began. Specifically, Wyeth argues this action is time-barred because plaintiffs never filed a signed waiver of service form and, as a result, the statute of limitations was never tolled under Connecticut law. I granted leave to file the supplemental summary judgment motion in order to reach its merits (doc. #324). The motion is procedurally untimely and substantively meritless. Accordingly, the supplemental summary judgment motion (doc. # 326) is DENIED.

I. Background

This is a products liability action, before this court on diversity jurisdiction, involving combination hormone replacement therapy (“cHRT”) products that allegedly caused breast cancer. The plaintiffs are Kenneth Moss, as executor for his late wife, Lynn Gardner Moss, and Kenneth Moss, individually. Lynn Gardner Moss (“Mrs. Moss”) passed away in December 2006 after a protracted battle with breast cancer. Wyeth is a pharmaceutical company that manufactures the hormone therapy drugs Premarin, an estrogren, and Prempro, a combination of Premarin and a progestin, which are both prescribed to combat the symptoms of menopause. Plaintiffs claim that Premarin and Prempro were unreasonably dangerous, that Wyeth promoted the drugs without adequate warnings and without adequate clinical trials examining their safety, and that Mrs. Moss’s use of the drugs was a substantial contributing factor in her development of breast cancer.

On June 10, 2003, the Multi-District Litigation (“MDL”) judge presiding over the Prempro product liability litigation, of which this case later became a part, issued [157]*157a series of practice and procedure orders, including the following:

Wyeth has agreed to waive service of summons pursuant to Fed.R.Civ.P. 4(d) in federal cases subject to transfer pursuant to 28 U.S.C. § 1407. Wyeth is relieved of the obligation to answer any complaint not yet answered and the complaints in subsequent tag-along actions, and the answers filed in [previous Prempro cases] will be deemed the answers in such actions.

Practice and Procedure Order No. 1, at § 2.5, attached as Ex. A to Pis.’ Opp’n (doc. # 283).

Plaintiffs filed their tag-along complaint on September 10, 2004 (doc. # 1). In keeping with the MDL order above, plaintiffs mailed Wyeth a copy of the complaint with a waiver form and a notice explaining the waiver procedure, which Wyeth’s representative signed on October 5, 2004. See Waiver of Service of Summons, attached as Ex. B to Defs.’ Mem. (doc. # 280-11). Wyeth returned the executed waiver to plaintiffs’ counsel and promptly filed an appearance in this court on October 6, 2004 (doc. # 4). Thereafter, the case was conditionally transferred, with like cases from around the country, for initial proceedings in the Eastern District of Arkansas (doc. # 10). Plaintiffs, however, never filed the signed waiver form with the court as contemplated under Fed.R.Civ.P. 4(d). That alleged misstep is at the heart of Wyeth’s present motion.

On January 18, 2005, while the case was still pending in the MDL court, Wyeth filed its Master Answer. See Master Answer, attached as Ex. C to Pis.’ Opp’n (doc. #283). The Answer asserted numerous affirmative defenses, including a statute of limitations defense, but made no mention of insufficient service of process or lack of personal jurisdiction. See id. In fact, over the course of the next half-decade of discovery and motions practice, Wyeth never once raised the issue of defective service.

On April 14, 2010, after the conclusion of the MDL proceedings, the case was remanded back to this court for dispositive motions and trial (doc. # 15). I ordered that all dispositive motions be filed by November 23, 2011 (doc. # 112). On that date, Wyeth filed a motion for summary judgment on multiple grounds, including the statute of limitations (doc. # 143). Notably, however, none of Wyeth’s arguments in favor of summary judgment related to insufficient service or the relevant commencement date of the lawsuit. Rather, Wyeth’s statute of limitations defense focused solely on when plaintiffs’ cause of action accrued. Wyeth argued that the three-year limitations period on all of plaintiffs’ claims started to run on October 22, 1999, the date Mrs. Moss was first diagnosed with cancer, and therefore expired before plaintiffs filed their complaint almost five years later on September 10, 2004.

At a hearing on March 1, 2012, I denied Wyeth’s summary judgment motion in substantial part (doc. # 221).1 2 On the statute of limitations issue in particular, I conclud[158]*158ed that plaintiffs had raised an issue of fact whether Mrs. Moss could have known that Wyeth’s drugs were to blame for her cancer before July 9, 2002 — the date the Women’s Health Initiative (“WHI”) study was released to the general public showing a causal link between cHRT and breast cancer. See Mot. Hr’g Tr. (doc. # 227), at 87-89.3 Thus, I ruled that it was for the jury to decide whether Mrs. Moss could have reasonably discovered “actionable harm” by Wyeth before the limitations period lapsed. See Bogdan v. Zimmer, Inc., 165 Fed.Appx. 883, 884 (2d Cir.2006) (construing “injury” under Conn. Gen.Stat. § 52-577a as “actionable harm” and emphasizing that “ ‘actionable harm’ does not occur until the plaintiff discovers an injury and causation”) (quoting Lagassey v. State, 268 Conn. 723, 743, 846 A.2d 831 (2004)) (emphasis in original). Should the jury agree that Mrs. Moss’s cause of action accrued on July 9, 2002, her claims were timely so long as they were brought before July 9, 2005. It bears mentioning, however, that at no point during that hearing, or in any subsequent pretrial motion or proceeding, did Wyeth raise the issue of defective service or the commencement date of suit.

On May 3, 2012, the same day jury selection was conducted, Wyeth filed a motion for leave to file a supplemental motion for summary judgment (doc. #280). I granted the motion for leave in order to reach the merits of the supplemental summary judgment motion (doc. #324). In this latest motion, Wyeth proposes a new spin on its statute of limitations defense. Instead of focusing on the date the cause of action accrued, Wyeth now focuses on the date the lawsuit commenced. Wyeth argues that, because plaintiffs never filed the signed waiver of service form, this action never formally commenced under Connecticut law. As a result, Wyeth argues, the statute of limitation was never tolled and has since expired.

II. Discussion

Free access — add to your briefcase to read the full text and ask questions with AI

Related

McArthur v. Summit Security
D. Connecticut, 2022
Khan v. Yale University
D. Connecticut, 2021
Sun v. Mashantucket Pequot Gaming Enterprise
309 F.R.D. 157 (D. Connecticut, 2015)
Tobin v. Gluck
11 F. Supp. 3d 280 (E.D. New York, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
872 F. Supp. 2d 154, 2012 U.S. Dist. LEXIS 69178, 2012 WL 1802445, Counsel Stack Legal Research, https://law.counselstack.com/opinion/moss-v-wyeth-inc-ctd-2012.